Centocor, Fujisawa deal

Fujisawa received exclusive distribution rights in Japan to CNTO's ReoPro anti-platelet antibody. Fujisawa will pay a $15 million upfront payment, $12 million in milestone payments, and pay for all Japanese development and marketing costs.

ReoPro is approved in the U.S. for use in high-risk angioplasty. CNTO said Phase II studies in Japan will begin later this year for the same indication. ...